Ventripoint to Showcase VMS+ 4.0 at AEPC 2026, Emphasizing Lifelong Cardiac Monitoring for CHD Patients

Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026 in Padua, Italy. The AEPC, founded in 1963, is the largest association in congenital cardiology worldwide, uniting over 1,000 specialists from 32 European countries and beyond. This year's meeting, hosted by the University of Padova, focuses on advanced cardiovascular imaging and artificial intelligence—areas where Ventripoint is driving clinical progress.

Ventripoint will exhibit alongside its European distributor, AngioPro, engaging with clinicians from the global congenital cardiology community. A key focus will be the ability of VMS+™ to track cardiac function over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for longitudinal ventricular function assessment (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).

Ventripoint's priority for 2026 is accelerating integration of VMS+™ into routine practice. The latest release, VMS+™ 4.0, streamlines workflows and reduces assessment time, making advanced cardiac analysis accessible at the point of care. It provides volumetric measurements equivalent to MRI from a patient's first echocardiogram, supporting clinical decision-making across a lifetime of care. “AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI—giving clinicians the confidence they need to manage their patients at every stage of life.”

Ventripoint Diagnostics Ltd. is an industry leader in applying artificial intelligence to echocardiography. Its VMS+™ product family, powered by proprietary KBR technology, delivers volumetric cardiac measurements with accuracy equivalent to MRI. VMS+™ is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada. The company's forward-looking statements are subject to risks and uncertainties as detailed in its annual management's discussion and analysis available on SEDAR.